Literature DB >> 9699182

Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers.

M S Tsao1, N Liu, J R Chen, J Pappas, J Ho, C To, J Viallet, M Park, H Zhu.   

Abstract

Hepatocyte growth factor (HGF)/scatter factor (SF) is a multifunctional factor that stimulates epithelial cell motility, invasion and morphogenesis. Its receptor is a transmembrane tyrosine kinase encoded by the Met proto-oncogene. Several studies have suggested a possible role for HGF/Met in tumor development and progression. To investigate the potential roles of Met in human lung cancer biology, we have studied the mRNA and protein expression of Met in normal lung tissue, primary non-small cell lung carcinoma (NSCLC), and NSCLC cell lines. The results indicated a differential pattern of Met expression among various subtypes of NSCLC. The majority of squamous cell carcinoma (SQCC), either in vivo or in vitro, expressed Met mRNA and its protein product at levels much lower than or similar to normal lung tissue or bronchial epithelium. Moreover, SQCC characteristically over-expressed a variant Met mRNA which corresponds to a 5' partially deleted transcript produced by alternative splicing. In contrast, the expression of Met mRNA and its protein product in adenocarcinoma (ADC) and large cell undifferentiated carcinoma were more heterogeneous. Overexpression was demonstrated in approximately 35% and 20% of these subtypes of NSCLC, respectively. Among ADC, intermediate to high levels of Met immunoreactivity correlated with greater degree of tumor differentiation. Furthermore, an accentuation of Met immunoreactivity was often noted in cancer cells at the advancing edge of tumors. These findings support a role for Met in lung cancer cell invasion and differentiation in vivo, but its expression and functions may be modified by the differentiation phenotype of the tumor cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9699182     DOI: 10.1016/s0169-5002(98)00007-5

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  43 in total

1.  Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer.

Authors:  Shuying Liu; Shunqiang Li; Bailiang Wang; Wenbin Liu; Mihai Gagea; Huiqin Chen; Joohyuk Sohn; Napa Parinyanitikul; Tina Primeau; Kim-Anh Do; George F Vande Woude; John Mendelsohn; Naoto T Ueno; Gordon B Mills; Debu Tripathy; Ana M Gonzalez-Angulo
Journal:  Mol Cancer Ther       Date:  2018-12-05       Impact factor: 6.261

2.  Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line.

Authors:  S Yi; M S Tsao
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

3.  An overview of the c-MET signaling pathway.

Authors:  Shawna Leslie Organ; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

Review 4.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

5.  Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status.

Authors:  Jaemoon Koh; Heounjeong Go; Bhumsuk Keam; Moon-Young Kim; Soo Jeong Nam; Tae Min Kim; Se-Hoon Lee; Hye Sook Min; Young Tae Kim; Dong-Wan Kim; Yoon Kyung Jeon; Doo Hyun Chung
Journal:  Mod Pathol       Date:  2015-07-17       Impact factor: 7.842

Review 6.  Biology of MET: a double life between normal tissue repair and tumor progression.

Authors:  Iacopo Petrini
Journal:  Ann Transl Med       Date:  2015-04

Review 7.  MET overexpression and gene amplification in NSCLC: a clinical perspective.

Authors:  Lorenza Landi; Gabriele Minuti; Armida D'Incecco; Jessica Salvini; Federico Cappuzzo
Journal:  Lung Cancer (Auckl)       Date:  2013-06-18

8.  Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.

Authors:  Roya Navab; Jiang Liu; Isolde Seiden-Long; Warren Shih; Ming Li; Bizhan Bandarchi; Yan Chen; Davina Lau; Yen-Fen Zu; Dave Cescon; Chang Qi Zhu; Shawna Organ; Emin Ibrahimov; Dina Ohanessian; Ming-Sound Tsao
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

Review 9.  MET as a target for treatment of chest tumors.

Authors:  Nicole A Cipriani; Oyewale O Abidoye; Everett Vokes; Ravi Salgia
Journal:  Lung Cancer       Date:  2008-07-30       Impact factor: 5.705

10.  Role of c-Met in cancer: emphasis on lung cancer.

Authors:  Ravi Salgia
Journal:  Semin Oncol       Date:  2009-04       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.